MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2022

The measures to increase the pace of patient recruitment have yielded results. The Fostrox study is now progressing as expected.July – SeptemberFinancial summary for the quarter · Net turnover amounted to SEK 1.1 (0.8) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -13.9 (-11.7) million. Basic and diluted earnings per share amounted to SEK -0.27 (-0.24) and SEK -0.27 (-0.24) respectively. · Cash flow from operating activities amounted to SEK -19.7 (-20.0) million. · Cash and cash equivalents at the end of the period